Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$10.31 USD
+0.03 (0.29%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $10.30 -0.01 (-0.10%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FOLD 10.31 +0.03(0.29%)
Will FOLD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FOLD
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
Other News for FOLD
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Amicus (FOLD) Gets a Buy from TD Cowen
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
3 Biotech Names Under $10 I Own